Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR4 | Q13639 | 5/20 | 0.52 |
| ▸ | DRD4 | P21917 | 4/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.49 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.49 |
| ▸ | HTR2B | P41595 | 1/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.49 |
| ▸ | HTR3A | P46098 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991625 | 0.85 | GRM5 (0.49) | DRD3 | |
| SCHEMBL989512 | 0.83 | GRM5 (0.45) | — | |
| SCHEMBL990083 | 0.83 | L3MBTL1 (0.47) | — | |
| SCHEMBL990847 | 0.82 | GRM5 (0.49) | — | |
| SCHEMBL990999 | 0.81 | GRM5 (0.56) | — | |
| SCHEMBL990807 | 0.81 | GRM5 (0.52) | — | |
| SCHEMBL992266 | 0.80 | L3MBTL1 (0.46) | — | |
| SCHEMBL990822 | 0.80 | NPC1 (0.48) | — | |
| SCHEMBL1907158 | 0.80 | GRM5 (0.46) | — | |
| SCHEMBL2815651 | 0.80 | GRM5 (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150272929-A1 | ORGANIC COMPOUNDS | UMBRICHT DANIEL (CH) | 2015-10-01 | — | — | US | disclosed |
| EP-2826478-A1 | COMBINATIONS COMPRISING MGLUR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2015-01-21 | — | — | EP | disclosed |
| US-20140194423-A1 | COMBINATION PRODUCTS | GOMEZ-MANCILLA BALTAZAR (CH) | 2014-07-10 | — | — | US | disclosed |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2014-07-03 | — | — | US | disclosed |
| US-8703809-B2 | Combination products | NOVARTIS AG (CH) | 2014-04-22 | — | — | US | disclosed |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GLATTHAR RALF (DE) | 2012-12-06 | — | — | US | disclosed |
| US-20120122878-A1 | COMBINATION PRODUCTS | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| EP-2272509-A1 | New Uses of metabotropic glutamate receptors | Novartis AG (CH) | 2011-01-12 | — | — | EP | disclosed |
| US-20100249136-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-09-30 | — | — | US | disclosed |
| EP-2211859-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE | Novartis AG (CH) | 2010-08-04 | — | — | EP | disclosed |
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NOVARTIS AG | 2010-04-22 | — | — | US | disclosed |
| US-7696379-B2 | Acetylene derivatives | NOVARTIS AG (CH) | 2010-04-13 | — | — | US | disclosed |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | RALF GLATTHAR | 2010-02-18 | — | — | US | disclosed |
| EP-2069305-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Novartis AG (CH) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009047296-A2 | METABOTROPIC GLUTAMATE RECEPTOR MODULATORS FOR THE TREATMENT OP PARKINSON'S DISEASE | NOVARTIS AG (CH) | 2009-04-16 | — | — | WO | disclosed |
| US-20080214673-A1 | Acetylene Derivatives | NOVARTIS AG (CH) | 2008-09-04 | — | — | US | disclosed |
| WO-2008031550-A2 | NICOTINIC ACID DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTANATE RECEPTORS | NOVARTIS AG (CH) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099682-A1 | ACETYLENE DERIVATIVES | NAT1, NAT10, F12 | HTR4 4156/4885DRD4 2076/4885DRD2 1944/4885 |
| US-20100041641-A1 | USES OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | HTR4 184/4885DRD4 462/4885DRD2 318/4885 |
| US-20120309742-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | HTR4 172/4885DRD4 420/4885DRD2 268/4885 |
| US-20140187600-A1 | USE OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | HTR4 172/4885DRD4 420/4885DRD2 268/4885 |
| US-20120122878-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | HTR4 134/4885DRD4 79/4885DRD2 41/4885 |
| US-20150272929-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | HTR4 45/4885DRD4 133/4885DRD2 111/4885 |
| US-20140194423-A1 | COMBINATION PRODUCTS | GRM5, GRM2, GRM1 | HTR4 134/4885DRD4 79/4885DRD2 41/4885 |
| US-20100249136-A1 | ORGANIC COMPOUNDS | GRM5, GRM2, GRM4 | HTR4 45/4885DRD4 133/4885DRD2 111/4885 |
| US-20080214673-A1 | Acetylene Derivatives | NAT1, NAT10, F12 | HTR4 4156/4885DRD4 2076/4885DRD2 1944/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.